FY2016 Earnings Forecast for Biocept Inc. (BIOC) Issued By Roth Capital
Biocept Inc. (NASDAQ:BIOC) – Research analysts at Roth Capital boosted their FY2016 earnings per share (EPS) estimates for shares of Biocept in a research note issued to investors on Wednesday. Roth Capital analyst C. Lewis now expects that the brokerage will post earnings of ($2.26) per share for the year, up from their prior forecast of ($2.30). Roth Capital also issued estimates for Biocept’s Q4 2016 earnings at ($0.35) EPS, Q1 2017 earnings at ($0.32) EPS, Q2 2017 earnings at ($0.30) EPS, Q3 2017 earnings at ($0.27) EPS, Q4 2017 earnings at ($0.25) EPS and FY2017 earnings at ($1.14) EPS.
Other equities analysts also recently issued research reports about the company. Feltl & Co. downgraded Biocept from a “buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Zacks Investment Research downgraded Biocept from a “buy” rating to a “hold” rating in a research note on Tuesday, July 19th. Finally, Rodman & Renshaw set a $2.50 target price on Biocept and gave the stock a “buy” rating in a research note on Wednesday, August 31st. Five equities research analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus target price of $2.14.
Biocept (NASDAQ:BIOC) opened at 0.863 on Monday. The firm’s 50-day moving average price is $1.10 and its 200-day moving average price is $1.74. Biocept has a 1-year low of $0.74 and a 1-year high of $6.03. The company’s market cap is $7.25 million.
Biocept (NASDAQ:BIOC) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.57) EPS for the quarter, hitting the Zacks’ consensus estimate of ($0.57). Biocept had a negative return on equity of 764.73% and a negative net margin of 876.22%. The firm had revenue of $1.05 million for the quarter.
A hedge fund recently raised its stake in Biocept stock. Vanguard Group Inc. increased its stake in Biocept Inc. (NASDAQ:BIOC) by 7.9% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 411,214 shares of the company’s stock after buying an additional 29,949 shares during the period. Vanguard Group Inc. owned approximately 1.65% of Biocept worth $273,000 as of its most recent SEC filing. Institutional investors own 9.93% of the company’s stock.
In related news, SVP Lyle J. Arnold bought 45,000 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were purchased at an average price of $1.10 per share, for a total transaction of $49,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Claire Reiss bought 227,272 shares of the company’s stock in a transaction on Wednesday, October 19th. The shares were bought at an average price of $1.10 per share, for a total transaction of $249,999.20. The disclosure for this purchase can be found here. 6.80% of the stock is owned by corporate insiders.
Biocept, Inc is an early commercial-stage molecular oncology diagnostics company. The Company develops and commercializes circulating tumor cell (CTC) and circulating tumor deoxyribonucleic acid (ctDNA), assays utilizing a standard blood sample, or liquid biopsy. The Company’s Target-Selector offering is based on an internally developed, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing can be used by clinicians by providing biomarker detection and monitoring requiring only a standard blood sample.
Receive News & Stock Ratings for Biocept Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept Inc. and related stocks with our FREE daily email newsletter.